Breast Neoplasms, Male

• 

  Subject Areas on Research

  • A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. 
  • A role for the androgen receptor in the treatment of male breast cancer. 
  • ASO Author Reflections: What is the Most Appropriate Surgical Management for Men with Breast Cancer? 
  • Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. 
  • BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. 
  • Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. 
  • Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis. 
  • Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. 
  • Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. 
  • Genetic/familial high-risk assessment: breast and ovarian. 
  • Histiocytoid carcinoma of the male breast. 
  • Identification of the breast cancer susceptibility gene BRCA2. 
  • Juvenile papillomatosis of the breast in male infants: two case reports. 
  • Male breast cancer during treatment with leuprolide for prostate cancer. 
  • Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. 
  • Management of Male Breast Cancer: ASCO Guideline. 
  • Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. 
  • Surgery for Men with Breast Cancer: Do the Same Data Still Apply? 
  • The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. 
  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. 
  • Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.